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Abstract
Background: Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a
relatively non-invasive source of representative tumor material. Circulating Tumor Cells (CTCs) isolated from blood of
metastatic cancer patients hold significant promise in this regard.
Methodology/Principal Findings: Using spiked tumor-cells we evaluated CTC capture on different CTC technology
platforms, including CellSearchH and two biochip platforms, and used the isolated CTCs to develop and optimize assays for
molecular characterization of CTCs. We report similar performance for the various platforms tested in capturing CTCs, and
find that capture efficiency is dependent on the level of EpCAM expression. We demonstrate that captured CTCs are
amenable to biomarker analyses such as HER2 status, qRT-PCR for breast cancer subtype markers, KRAS mutation detection,
and EGFR staining by immunofluorescence (IF). We quantify cell surface expression of EGFR in metastatic lung cancer
patient samples. In addition, we determined HER2 status by IF and FISH in CTCs from metastatic breast cancer patients. In
the majority of patients (89%) we found concordance with HER2 status from patient tumor tissue, though in a subset of
patients (11%), HER2 status in CTCs differed from that observed in the primary tumor. Surprisingly, we found CTC counts to
be higher in ER+ patients in comparison to HER2+ and triple negative patients, which could be explained by low EpCAM
expression and a more mesenchymal phenotype of tumors belonging to the basal-like molecular subtype of breast cancer.
Conclusions/Significance: Our data suggests that molecular characterization from captured CTCs is possible and can
potentially provide real-time information on biomarker status. In this regard, CTCs hold significant promise as a source of
tumor material to facilitate clinical biomarker evaluation. However, limitations exist from a purely EpCAM based capture
system and addition of antibodies to mesenchymal markers could further improve CTC capture efficiency to enable routine
biomarker analysis from CTCs.
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Introduction
Oncology drug discovery efforts are increasingly focused on
targeted therapies that inhibit major nodes of oncogenic
signaling pathways. A key to successful development of such
agents is the ability to pre-select patients that will experience
clinical benefit through molecular analysis of tumor tissue and
the identification of predictive biomarkers that can match a drug
with appropriate patients [1,2,3,4]. Examples that illustrate the
power of this approach are the HER2-targeting antibody trastu-
zumab (HerceptinH), which was successfully developed specifi-
cally in patients with tumor overexpression or amplification of
HER2 [5], and the EGFR tyrosine kinase inhibitors gefitinib
(Iressa) and erlotinib (TarcevaH), which have shown dramatic
anti-tumor activity in patients whose tumors harbor oncogenic
mutations in EGFR [6].
Available and representative tumor tissue is essential for
biomarker assessment but can be difficult to obtain from patients
with certain tumor types. An example is advanced stage non small-
cell lung cancer (NSCLC), where surgery is frequently not a
component of treatment and diagnosis is done with small biopsies
or fine needle aspirates that yield only very limited tissue quantities
[7]. Even in cases where primary tissue is available, the samples
may not be representative of a patient’s metastatic disease, which
may arise many years after diagnosis and after a variety of
therapeutic interventions. A primary example is prostate cancer,
which often presents with multifocal localized disease but can often
have a long indolent period of 10–15 years before it progresses to
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obtaining tissue from a fresh biopsy is challenging in this indication
as the metastatic lesions are often localized to bone [9,10]. Even if
such material can be obtained, it is unclear whether a biopsy from
a single site is representative of the majority of metastatic lesions
and cases of marked heterogeneity have been reported [10].
Similar considerations are also true for metastatic breast cancer,
where tumor samples may be limited to tissue from the primary
disease site, which again, may be separated from disease
recurrence by both time and treatment [11]. Collection of
representative tumor material is clearly an important hurdle that
must be overcome in successful biomarker development.
It has been known for over a hundred years that disseminated
tumor cells can be found in the circulation of patients with
metastatic cancer [12], and it has been hypothesized that these
circulating tumor cells (CTCs) may represent cancer stem cells or a
high metastatic potential cellular population [13]. In recent years,
significant effort has been put into developing technologies that
achieve specific and sensitive detection and capture of CTCs
[14,15], which is a major challenge since as few as one CTC may
be found in the background of 105–106 peripheral blood
mononuclear cells [16]. The CellSearchH platform uses immuno-
magnetic beads coated with antibodies to Epithelial Cell Adhesion
Molecule (EpCAM) [17] to enrich for EPCAM-expressing
epithelial cells, followed by immunostaining to confirm the
presence of cytokeratin staining and absence of the leukocyte
marker CD45 to confirm that captured cells are epithelial tumor
cells [18]. The number of cells captured in this assay has been
prospectively demonstrated to have prognostic significance for
breast, colorectal and prostate cancer patients with advanced
disease [19,20,21,22].
In addition to prognostic utility, CTCs are an attractive
alternative to tumor tissue for biomarker analysis that might help
address some of the challenges described above [2,13,23]. One
reason is accessibility and ease of collection, since CTCs can be
obtained from a routine blood draw with minimal risk and
inconvenience to the patient compared to a fresh biopsy. Another
appealing facet of CTCs as a surrogate diagnostic tissue is the idea
that CTCs could constitute a ‘‘liquid biopsy’’ and provide real-
time information about the patient’s current disease state [24,25].
Analysis of biomarker status in CTCs collected prior to treatment
could potentially be used to select an appropriate targeted therapy,
while repeated longitudinal sampling during treatment could be
used to detect appearance of resistance markers and potentially
enable switching to a more appropriate therapy. For CTCs to fill
this important niche, it is essential to demonstrate that they share
molecular characteristics with a patient’s solid tumor masses and
that biomarker status in CTCs is reflective of biomarker status in
neoplastic cells within tumor masses. An important recent advance
that may facilitate molecular characterization of CTCs is the
CTC-Chip, a microfluidic based CTC capture device where blood
flows through a chamber containing thousands of microposts
coated with anti-EpCAM antibodies to which the CTCs bind [26].
Importantly, reports on the CTC-Chip claim a significant increase
in CTC counts and purity in comparison to the CellSearchH
system [26,27]. Both platforms have shown some prior evidence of
utility for downstream molecular analysis. Examples include
immunofluorescence for IGF-1R and the DNA damage response
marker, gH2AX, in Phase I studies [28,29], EGFR[7] and
HER2[30] status in breast cancer, FISH for PTEN and FISH and
RNA for TMPRSS2-ERG fusion in prostate cancer[24,31], and
genotyping for EGFR mutations in lung cancer[27].
Here we report a series of experiments that address two
important challenges that must be answered if CTCs are to be
routinely used for biomarker assessment. First, we compared the
technical feasibility of isolating CTCs on different platforms,
including CellSearchH and two commercially available CTC-chip
platforms, and then used the captured CTCs for various
downstream molecular analyses commonly used in biomarker
assessment. Second, we evaluated whether the status of biomarkers
such as HER2 in captured CTCs faithfully reflects biomarker
status in matched tumor samples. To our knowledge, this is the
first head-to-head comparison of CellSearchH and CTC-chip
technologies, and overall we found similar performance in terms of
CTC enumeration and the influence of EpCAM expression levels
on capture rates. Secondly, our findings indicate that captured
CTCs are amenable to biomarker analyses such as HER2 status,
qRT-PCR for breast cancer subtype markers, KRAS mutation
detection, and EGFR staining by IF. Finally, we find that the
status of biomarkers such as HER2 in captured CTC generally
reflects biomarker status in matched tumor samples.
Materials and Methods
Ethics Statement
Breast cancer patient samples. Patient blood was procured
for this study by Open Biosystems (www.openbiosystems.com). All
specimens were obtained with written informed consent and
collected using a protocol approved by the Western Institutional
Review Board (www.wirb.com). Patient information: All patients
were Stage IV metastatic breast cancer patients, currently on
active treatment. A list of patient information including HER2
testing and available treatment history is provided in Table S1.
Non-small-cell lung cancer patient samples. All patient
samples were obtained as part of an ongoing Phase II clinical trial
and is listed at http://clinicaltrials.gov/ct2/show/NCT00855894.
All samples were collected and analyzed with written informed
consent.
EpCAM Expression Analysis
Expression of EpCAM and other genes in a panel of breast
cancer cell lines was determined by microarray profiling on
Affymetrix HGU133Plus_2.0 chips (Santa Clara, CA), as
previously described [32,33]. To examine the expression of
marker genes in primary tumors, gene expression profiles were
extracted from the commercially available database BioExpress
(GeneLogic, Gaithersburg MD). Cell surface expression of
EpCAM in breast cancer cell lines was evaluated by FACS (BD
Caliber) using an anti-EpCAM biotinylated antibody (R&D
Systems, BAF960) and streptavidin secondary.
Tumor-cell Spike-in into Blood
Ten milliliters (ml) of blood from healthy donors were collected
in appropriate blood tubes: CellSave for CellSearch, ACD for
OncoCEE and EDTA for On-Q-ity CTC-chips. Tumor cells from
culture cell lines were made into a 5000 cell/ml suspension and
necessary volumes were spiked into the 10 ml blood tube of
normal donor blood. Concurrently, an additional five spike-in
volumes were dispensed onto microscope slides for manual
counting to determine mean and range for spike-in. CTC counts
obtained from CellSearchH or CTC-Chip platforms were divided
by mean CTC count (based on spike-in count calculation) to
determine percent CTC recovery, for additional detail see Figure
S3. Time delay analysis: Spiked blood samples were stored at
ambient temperature and analyzed in house at Genentech at the
indicated time or sent to the collaborators and simultaneously
analyzed on their platforms at 24 h and 48 h time points.
Characterization of CTCs
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Samples run on CellSearchH were evaluated either at
Genentech or at one of two reference laboratories as indicated
in the figure legend. Reference Lab 1 is Apocell Biosciences
(Houston, TX) and Reference Lab 2 is Veridex LLC Pharma
Services (Huntington Valley, PA). CTC enumeration on Cell-
SearchH was carried out according to manufacturers training and
protocol [34], Veridex LLC (Raritan, NJ). CTC enumeration and
analysis on the microfluidic CTC-chips were run at two reference
labs that manufacture their own CTC-chip platforms: OncoCEE
microchannel (Biocept Inc, San Diego, CA) and On-Q-ity’s CTC-
Chip (On-Q-ity, Boston MA and previously CELLective Dx,
Menlo Park, CA). Cells were scored as CTCs on both CTC-chip
platforms as per the following criteria: Cytokeratin+, CD45- and
DAPI+. All samples sent for analyses on the CTC-chip platforms
or at reference labs were blinded to them.
EGFR and HER2 Immunophenotyping Assays
Spiked blood samples were processed on CellSearchH using the
CellSearchH Tumor Phenotyping Reagent EGFR or HER2
(Veridex, LLC). H-scores were calculated using the method of
McCarty, et al [35].
qRT-PCR Molecular Subtyping Assay
Breast cancer cell lines corresponding to the breast molecular
subtypes: Basal-like (HCC70), Luminal (T47D) and HER2
amplified (SKBR3) cells were spiked into normal donor blood
collected into EDTA tubes, using donor blood alone as a control.
Samples were processed on CellSearchH using the CellSearch
RUO Profile kit (Veridex LLC). RNA was extracted from the
isolated CTCs and qRT-PCR analysis performed using a
TaqManH low density array, TLDA, (Applied Biosystems, Foster
City CA) with subtype specific genes [36].
HER2 FISH Assay
FISH analysis on CellSearchH was done by Veridex Clinical
Research Solutions (Veridex, Huntington Valley, PA) using the
RF Poseidon
TM Rare Cell HER-2 FISH assay (Veridex LLC).
CTCs were captured and enumerated in the cartridge using the
CellSearchH Assay. For FISH processing CTCs were fixed in the
CellSearchH cartridge and hybridized with the HER-2/SE17
FISH assay. CTCs were relocated and scored using a CellTracksH
Analyzer modified with a 40x objective and special software for
relocating CTCs. FISH analysis on the OncoCEE Microchannel
CTC-Chip was done by Biocept, Inc, using the PathVysion HER2
FISH kit (Abbott Laboratories, Abbott Park, IL). CTCs were first
identified by standard criteria (CK+, CD45-, DAPI+). In addition,
an automated cell locator was used to record the X and Y
coordinates of each CTC. Following FISH processing, CTCs were
re-identified based on location and cytokeratin positive staining
and nuclei were scored for copies of HER2 and CEP17. HER2
gene amplification was defined as a ratio of .2 for hybridization
signals from a HER2 locus specific probe to Chromosome 17
probe, and an average number of gene copies/cell of 4 or greater.
KRAS Mutation Detection Assay
KRAS mutant H2122 cells were spiked into blood (10, 100,
1000 or 10000 cells in 10 ml blood). Spiked-in tumor cells were
captured on CellSearchH using the RUO Profile kit. CTCs bound
to ferrofluids were separated using the Magcellect magnet (R&D
systems, Minneapolis, MN) and DNA extracted using the Picopure
DNA extraction kit (Molecular Devices, Sunnyvale, CA) by
overnight lysis. The full volume of extracted DNA was subjected
to a preamplification reaction using KRAS exon 2 primers
followed by PCR on the Fluidigm Digital Array platform
(Fluidigm, South San Francisco, CA) using a Taqman genotyping
assay for the KRAS mutation G12C, with the probe designed to
detect the presence of the mutant amplicon. Primer and probe
sequences were as follows: reverse primer; GCTGTATCGT-
CAAGGCACTCTTG, forward; GGCCTGCTGAAAATGACT-
GAA and mutant MGB VIC labeled probe; TTGGAGCT-
TGTGGCG.
Results
Prevalence of EpCAM expression and impact of
differences on CTC capture
EpCAM (also know as TACSTD1) is well characterized as a
marker of epithelial tumor cells [37] and anti-EpCAM antibodies
have been widely used in the capture of CTCs [14]. As a first step in
evaluating CellSearchH in comparison with the CTC-Chip
platforms, all of which use EpCAM expression as the basis for
CTC capture, we looked at the utility of EpCAM as a universal
marker expressed on cancer cells by evaluating its expression in cell
lines and across diverse tumor types. We determined the distribution
of EpCAM mRNA expression across 50 breast cancer cell lines
representive of luminal, HER2 amplified and basal-like breast
cancers (Figure 1A) [32,36]. EpCAM expression was high, .7000
Affymetric units (AU), across the majority of cell lines (Figure 1a).
However, about 20% of the cell lines showed little to no EpCAM
expression (,500 AU). Interestingly, cell lines with low EpCAM
expression were primarily froma subset ofthe basal-like subtype that
showed high expression of the mesenchymal marker vimentin and
lowexpressionofepithelialmarkerssuchascytokeratins8,18 and19
and E-cadherin (Figure 1B). These cell lines have previously been
described as the Basal B subgroup and known to have higher
expression of mesenchymal markers, as well as certain stem cell-like
properties and a more invasive phenotype [36]. Importantly, EGFR
and c-Met were highly expressed in this subset, suggesting that
antibodies against these cell surface markers could have utility in
capturing this subset of breast cancer cells. This data suggests that
CTCs may be difficult to capture using a purely EpCAM-based
capture mechanism in a subset of basal-like breast cancers.
We also evaluated the distribution of EpCAM at the mRNA
level in patient tumor samples and found that while the majority of
tumor types showed high EpCAM expression, we again noticed
that a subset of samples from each tumor type had lower EpCAM
expression (Figure 1C). In particular, lung and ovarian cancer
samples had a greater percentage of tumor cells with very low
expression (Figure 1C). Again, we observed that low EpCAM
expression was associated with high vimentin expression (Figure
S1), suggesting that capture of mesenchymal tumors may be
challenging with EpCAM based-methods and that other capture
antibodies may be required to capture the full range of CTCs.
Evaluation of EpCAM-based capture using commercially
available CTC technologies
We first investigated a number of variables that could
conceivably affect CTC recovery and enumeration using the
CellSearchH platform, including EpCAM expression, CTC
number, time to analysis, and variations when samples are
analyzed in different reference labs using the same platform. For
this purpose we chose two breast cancer cell lines: SKBR3, which
has high EpCAM mRNA expression (.7000 AU) and CAL-120,
which has low mRNA expression (,500 AU). Expression at the
protein level was confirmed by FACS analysis (Figure S2). We
then developed a tumor cell spike-in protocol that enabled us to
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12517Figure 1. Evaluation of EpCAM as a marker for capturing CTCs. A. EpCAM expression in breast cancer cell lines grouped by molecular
subtype. B. Expression of EpCAM in relation to other epithelial and mesenchymal markers in breast cancer cell lines. C. EpCAM expression in different
tumor types and in white blood cells (WBC). D. Spike-in CTC recovery on CellSearchH (left panel) in EpCAM high and EpCAM low cells when analyzed
at 24 h or 48 h post spike-in at Genentech or two reference labs (Ref Lab). In the EpCAM-high (24 h) group, samples are graphed by individual spike-
in cell count (10–500 cells) and pooled together for all other groups.
doi:10.1371/journal.pone.0012517.g001
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recover as few as 10 spiked-in tumor cells from 7.5 ml whole blood
with a typical variability of +/230% (Figure S3). We next spiked
tumor cells from SKBR3 and CAL-120 into whole blood and
tested the recovery rate under different conditions using the
CellSearchH and CTC-chip platforms.
On the CellSearchH platform, we found that average CTC
recovery in the high EpCAM SKBR3 cell line was 75% or better
(Figure 1D), whereas in low-EpCAM CAL-120 cells CTC recovery
was significantly lower witha mean of 42% (p=2.0E-4, Student’s t-
Test). We found no significant change in recovery between 24 and
48 hours post analysis, but we observed that the EpCAM-low cells
did show a trend toward decreased recovery at 48 hours. We also
shipped SKBR3-spiked samples to two reference labs for analysis to
evaluate the effects of shipping, transport and multiple operators on
CTC recovery. Average CTC recovery using CellSearchH was
lower at a mean of 58% in the case of Reference Lab 1 (p=1.0 E-6)
in comparison to analysis done at Genentech. In the case of
Reference Lab 2, the data appeared more variable but overall
recovery was not statistically different (p=0.25).
We next evaluated two different commercially available micro-
fluidic CTC-chip platforms and compared the results to Cell-
SearchH. In general, average recovery of high EpCAM expressing
SKBR3 cells on both CTC-chip platforms was .75% and was
comparable to CellSearchH exceptat the 10-cell spike in level which
was less robust and varied to below 50% recovery on both CTC-
Chip platforms (Figure 1D, middle and right panels). In EpCAM-
low CAL-120 cells, average CTC recovery was below 50% on
CellSearchH and similarly low on the OncoCEE microchannel chip
platform (p=0.42), but improved to .50% on the On-Q-ity CTC-
chip (p=0.001). One caveat to the higher numbers observed on this
platform is that CTC recovery was substantially above 100%.
Spike-in recovery up to 130% could be attributed to the +/230%
error rate associated with spike-in, but beyond that might indicate
non-specificity in the assay, with blood cells possibly erroneously
scored as CTCs.
Technical feasibility of molecular biomarker assays using
CTCs
We next tested technical feasibility of using isolated CTCs in
assays that are most commonly used for biomarker assessment:
protein expression by immunofluorescence, DNA amplifications
by FISH, mRNA transcript expression by qRT-PCR and
oncogenic mutations in DNA by a q-PCR genotyping assay.
We tested if EGFR expression could be accurately determined
by immunofluorescence (IF) in CTCs using eight non-small-cell
lung cancer (NSCLC) cell lines with varying levels of EGFR
mRNA and known protein expression levels from IHC analysis on
tissue microarrays (Figure 2A). These cell lines were chosen such
that they had similar high EpCAM expression to ensure capture
was not a variable in this analysis. Using an EGFR antibody, we
evaluated the range of expression seen in CTCs isolated from
tumor-cell spike-in blood samples from four of the eight cell lines.
Instead of scoring EGFR by presence or absence of staining as
previously described[38], we developed a semi-quantitative
scoring criteria for EGFR expression levels based on staining
intensity and membrane localization (Figure 2B). These scoring
criteria were then used to score EGFR levels in captured spike-in
CTCs from the remaining four cell lines (Figure 2C). We observed
generally excellent agreement between EGFR staining in CTCs
and EGFR levels determined by IHC on cell pellets. Interestingly,
not all CTCs scored identically within a sample and in fact the
analysis indicated some heterogeneity in EGFR expression. A
weighted H-Score was then computed using the IF score and the
percentage of cells with that score, to provide a single value for
EGFR expression. H-score values correlated well with the EGFR
mRNA expression level in the cell lines (R2=0.91) and the cell
surface expression of these cell lines by FACS analysis (Figure S4),
indicating biomarker analysis based on levels of protein deter-
mined by IF may be feasible in captured CTCs.
HER2 gene amplification status by fluorescence in situ
hybridization (FISH) assay is routinely used to determine patient
eligibility for anti-HER2 therapies such as trastuzumab and
lapatinib [39,40,41]. We sought to determine whether a HER2
FISH assay could be reliably used to detect HER2 amplification in
CTCs. Tumor cells from the HER2 amplified cell line SKBR3 were
spiked into whole blood and cells were captured on the OncoCEE
microchannel chip platform and analyzed for HER2 FISH
(Figure 2D). We tested the robustness of this assay by evaluating
FISH on samples with as few as 2 CTCs and many as 159 CTCs
(Table 1). All samples with 3 or more CTCs showed a HER2 to
centromere 17 ratio of greater than two and would thus be classified
as HER2-amplified according to standard criteria [42].
We also evaluated whether qRT-PCR based multi-gene
expression analysis can be done from CTCs isolated on the
CellSearchH platform using blood samples spiked with breast
cancer cell lines representing each of the major breast cancer
subtypes. Specifically, we used T47D ER+ luminal cells, SKBR3
HER2-amplified cells, and HCC70 basal-like cells [32,33]. RNA
from captured spike-in CTCs was subjected to qRT-PCR analysis
using a panel of genes derived from the Sorlie ‘‘intrinsic set’’ of
genes that can distinguish between the molecular subtypes based
on subtype specific expression patterns [43], including estrogen
receptor (ER) and progesterone receptor (PGR) for the luminal
subtype, HER2 and GRB7 from the HER2 amplicon, and EGFR
and c-Met from the basal-like subtype. Gene expression analysis on
this panel of 12 genes show the expected subtype-specific gene
expression pattern for each of the cell lines at both the 100 cell and
10 cell spike-in range (Figure 3 and Figure S5, respectively), but
did not clearly discriminate between subtypes when less than 10
cells were spiked in. The sensitivity limitation of this assay is
affected by the leukocyte background, which is in the range of
1000–3000 cells per sample dependent on donor, and would give
CTC:WBC ratios of ,1:100 for sample with 10 CTCs and ,1:10
for sample with 100 CTCs.
Another potentially important use of CTCs for biomarker
analysis is detection of oncogenic mutations that may predict
response to targeted agents [1]. Genotyping assays such as allele-
specific PCR often only have sensitivity down to approximately
1% mutant DNA in a background of wild-type DNA [44], so wild-
type copies of the gene of interest from contaminating WBCs co-
isolated with CTCs might hamper detection of CTC-specific
mutations. We developed a mutation detection assay that could
tolerate contamination by wild-type DNA by starting with a gene
specific amplification on total CTC lysate, followed by Taqman
genotyping assays using digital PCR arrays, a critical step to
increase the specific concentration of the mutant DNA relative to
WT DNA (Figure 4A). Assay performance was demonstrated
using KRAS mutant H2122 cells spiked into blood at levels
ranging from 10 cells up to 10,000 cells per 7.5 ml of blood
(Figure 4B). The KRAS G12C mutation was detectable in DNA
from as few as 10 captured cells, with increasing numbers of
positive wells observed with the higher cell numbers.
Evaluation of EGFR expression and HER2 status in CTCs
from patients with metastatic disease
We used the EGFR IF assay to evaluate EGFR expression on
samples from 34 patients with metastatic NSCLC enrolled in a
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collected for CTC analysis prior to starting therapy, 24 patients
(70%) had at least one evaluable CTC with 50% of patients having
3 or more CTCs (Figure 5A), which is somewhat surprising given
the generally low level of CTCs reported in NSCLC patients [18].
In the 20 patients that EGFR expression data was collected, we
observed a range of EGFR expression and a mixture of
homogenous and heterogenous EGFR staining between samples.
A few patients had very heterogeneous expression with CTCs that
spanned from 0–3 in staining intensity and this was best observed
in patients with higher CTC counts (.7 CTCs), though some
patients with high CTC counts also had homogeneous EGFR
staining. These studies suggest it may be feasible to quantitate cell
surface expression of candidate biomarkers on CTCs in patients
Figure 2. EGFR IF and HER2 FISH in CTCs. A. mRNA expression of EGFR (diamonds) or EpCAM (bars) in NSCLC cell lines. IHC scores for EGFR from
tissue microarrays are indicated below. B. EGFR immunofluorescence (IF) scoring criteria for CTCs. For each scoring level, the range of high and low
expression are shown. C. EGFR IF scoring of spiked tumor cells isolated from blood. The weighted H-score from CTC analysis and corresponding IHC
score for that cell line is listed below for each sample. D. HER2 FISH assay in captured SKBR3 cells on the OncoCEE microchannel platform. Cells are
stained with anti-cytokeratin antibody (green), DAPI (blue), FISH probes against HER2 (red dots) and a centromeric probe, CEP17 (green dots).
doi:10.1371/journal.pone.0012517.g002
Characterization of CTCs
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12517with metastatic NSCLC, however, only about 50% of patients had
sufficient CTCs (.3) for assessing heterogeneity in expression,
suggesting that improvements in capture technologies will be
required to fully enable biomarker studies in CTCs from NSCLC
patients.
We next evaluated HER2 status in CTCs from 38 patients with
advanced metastatic breast cancer. CTC counts in the patient
samples indicated a distinct distribution in different subtypes. ER+
patients had the highest CTC counts (range: 0–30, median:8),
while lower CTC counts were seen in HER2+ patients (range: 0–
7, median:1) and in triple negative patients (range: 0–6, median:1)
(Figure 5B). To determine if the difference in CTC counts between
subtypes was significant, we used non-parametric statistical
methods. A population based Poisson distribution assumption
would not be a good fit here because the variance in CTC counts
is higher than expected from such a model. There was a significant
difference in CTC counts found among all subtypes (Kruskal-
Wallis method p-value =0.004) or between ER+ and others
(Mann-Whitney p-value =0.02).
Twenty-nine of these patients (76%) had at least 1 CTC that
was evaluable using the CellSearchH platform. We evaluated
HER2 at the protein (IF assay) and DNA levels (FISH assay) and
compared HER2 status in CTCs to HER2 status in patient tumor
samples determined by tumor IHC/FISH on archival tissue. A
previous report evaluating HER2 expression in CTCs on the
CellSearchH platform scored HER2 positivity based simply on the
presence of HER2 staining in 50% of the CTCs and reported
discordance in HER2 status when compared to primary tumor in
a third of the patient samples [30]. To allow more direct
comparisons to the HER2 IHC scores obtained from matched
tumors samples, we developed a scoring system to quantitate
HER2 expression using a 0–3+ score in CTCs (Figure 5C) and
then computed an H-score to provide a weighted score based on
the number of CTCs with a given level of expression.
The HER2 IF staining and computed H-score for the 29
patients with at least one evaluable CTC is shown in Figure 5D,
and we compared these scores with tumor IHC/FISH results.
Nine out of 12 patients (75%) whose CTCs had an H-score of 200
or more were HER2+ based on IHC/FISH analysis of archival
tissue. Correspondingly, 15 out of 17 patients whose CTCs had an
H-score of less than 200 had tumor IHC scores of 0, 1+ or 2+ and
were HER2- based on IHC/FISH analysis of archival tissue.
Thus, we observed 89% concordance overall (24 of 29 patients)
between HER2 status in CTCs and HER2 status in neoplastic
tissue samples. Under the assumption that a patient’s HER2 status
in the tumor represents the truth, we calculated what number of
CTCs would best balance the false positives (Type I error) and
false negatives (Type II error) and found that .3 CTCs can yield
robust results for determination of HER2 status (Table S2 and
Figure S6). We also asked if HER2 status changed with time or
treatment. In replicate sampling in a small subset of the same
patients, we found that HER2 status was generally stable in
samples from the same patient (Figure S7). Furthermore, a subset
of the HER2 positive patients in this study were on trastuzumab
treatment at the time of blood collection, however, we found no
significant difference in HER2 expression in the patient subset
currently on treatment with trastuzumab (Figure S7).
We also performed HER2 FISH using both CellSearchH and
the OncoCEE microchannel platform on CTCs in a subset of
patients from the IF study where it was possible to obtain
Table 1. Performance of the HER2 FISH assay on the
OncoCEE platform.
Sample CTC Count CTCs FISHed HER2/CEP17 ratio
1 159 20 2.949
2 151 20 3.13
3 140 20 2.74
4 72 20 3.74
5 41 20 3.688
6 37 20 3.33
7 17 16 failed
8 10 10 2.86
9 10 10 3.04
10 3 3 3.33
11 5 2 4.22
12 2 2 1.88
Spike-in CTC count upon capture and post-FISH processing and HER2/CEP17
ratios are indicated across a range of tumor cell spike-ins analyzed on the
OncoCEE microchannel platform.
doi:10.1371/journal.pone.0012517.t001
Figure 3. qRT-PCR assay for molecular subtyping of breast
cancer in CTCs. A. 100 cells were spiked into normal donor blood
from a luminal (T47D), HER2+ (SKBR3) and a basal-like breast cancer cell
line (HCC70) or negative control (WBC) and were isolated using the
CellSearchH platform, followed by qRT-PCR analysis with a panel of
genes specific for the three corresponding breast cancer subtypes.
Heatmap shows hierarchically clustered z-score normalized Ct values for
each gene.
doi:10.1371/journal.pone.0012517.g003
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nine out of 13 samples (69%) tested on the CellSearchH platform
had one or more CTCs that could be evaluated by FISH
(Figure 5D). HER2 status by FISH agreed with the HER2 status
from archival tissue for all nine of these patients. Though only one
of the four patients with HER2+ status in archival tissue had
CTCs amenable for FISH in this analysis, HER2 amplification
was detected in the majority of CTCs from this patient except in 3
out of 22 CTCs scored that had ,4 copies of HER2, None of the
22 WBC scored had .2 copies of HER2. Overall, the FISH
results were also concordant with the IF results for all of these
patients. In comparison, six out of twelve samples (50%) tested on
the OncoCEE microchannel platform yielded CTCs that could be
scored in the HER2 FISH assay (Figure 5D). FISH results for five
out of the six agreed with HER2 status from archival tissue and IF
on CTCs, with the exception of patient 3, who was HER2+ based
on archival tissue and CTC IF assay but FISH negative based on
HER2 FISH analysis on the OncoCEE platform.
Discussion
The advent of targeted cancer therapeutics has resulted in a
paradigm shift from treating all patients with high dose
chemotherapy to more personalized approaches based on tumor
genetics and biology [1,3,4]. Targeted therapies have the potential
benefit of greater efficacy and reduced toxicity, but also require
predictive biomarker assays to identify appropriate patients. A
practical challenge to biomarker-based patient selection is the
availability of relevant tumor material. Obtaining a tumor biopsy
in a patient with advanced disease may be scientifically desirable
but often is not a practical option. Circulating tumor cells thus
have tremendous potential to change our approach to biomarker
evaluation by providing a source of tumor material that is easily
accessible through a blood draw. An additional potential benefit is
that CTC molecular characteristics may in some cases be more
representative of the patient’s current disease than archival tumor
tissue obtained years before at the time of diagnosis.
An important challenge that must be met if CTCs are to
become widely used as a surrogate tissue for biomarker analyses is
that they must be present in sufficient numbers to allow molecular
characterization in the majority of patients. In the original report
published on the CTC-chip, the authors reported an average CTC
count of .50 CTC/ml and that 100% of patients across multiple
indications showed .5 CTCs/mL of blood [26], a significantly
higher prevalence and number than are typically described for the
CellSearchH platform [18]. Higher CTC counts on the CTC-chip
platform have been attributed to the unique engineering and
microfluidic properties of the device, since careful theoretical
modeling was used to optimize the balance between velocity and
sheer forces and thus maximize capture of CTCs on microposts
[26]. Gentle laminar flow across CTC-chip microposts coated or
‘‘functionalized’’ with anti-EpCAM antibodies has been suggested
to result in higher yields and purity of CTCs by maximizing CTC
contact with capture antibodies and minimizing forces that could
cause disruption of cellular integrity [45]. These studies suggested
that the CTC-chip technology might prove superior to the
CellSearchH platform in terms of utility for biomarker analyses
based on substantially increased sensitivity and greater yields of
CTCs for downstream molecular analyses [45]. However, a side-
by-side comparison of CTC-chip platforms with CellSearchH has
not been previously reported. In this study, we compared the
performance of commercially available CTC-chip devices to the
CellSearchH platform using the same conditions and samples from
our cell line spike-in model system, as well as samples from patients
with advanced metastatic breast cancer. We found that both
CellSearchH and the two CTC-chip platforms tested here were
effective at capturing high-EpCAM expressing cells, but efficiency
fell to below 50% for cells expressing lower EpCAM levels. The
On-Q-ity CTC-chip platform showed slightly improved capture in
this context, but recoveries greater than 100% suggested some
non-specificity in this assay. Thus, both CellSearchH and the
CTC-chip platforms may have difficulty capturing CTCs from
more mesenchymal tumor types, and could benefit from additional
capture antibodies directed at antigens with more prevalent
expression in mesenchymal tumors. Indeed, some evidence points
to CTCs undergoing epithelial mesenchymal transition (EMT) as
part of the process of dissociating from the original tumor mass
and initiating the metastatic process [46,47], further suggesting
that non-EpCAM-based capture methods could benefit both
Figure 4. KRAS mutation detection assay in CTCs. A. Schematic of digital PCR based mutation detection assay. B. Results of the KRAS G12C
mutationassay onDigital PCR arraysstartingfrom DNAisolatedfromKRAS mutanttumorH2122cellsspikedinto wholebloodin the indicated numbers.
doi:10.1371/journal.pone.0012517.g004
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surprisingly, we found higher CTC counts in ER+ breast cancer
patients than in HER2+ or triple negative patients. This may be a
reflection of the underlying molecular subtype and gene expression
patterns of these tumors since we observe high EpCAM expression
in the luminal subtype of breast cancer and weak expression of
Figure 5. EGFR expression and HER2 status in CTCs from metastatic cancer patients. A. EGFR scoring in CTCs from metastatic lung cancer
patient samples, scored according to criteria described in Figure 2B. B. CTC counts from 39 metastatic breast cancer patient samples listed by
subtype. C. HER2 IF scoring criteria showing the high and low range of expression. D. Quantification of HER2 scoring in CTCs. H-score for HER2 IF in
CTCs, HER2 status in patient tumor, CTC counts and HER2 FISH results in CTCs are listed in table below. HER2 FISH was performed on CellSearch (CS)
or on the OncoCEE microchannel (OncoCEE). For HER2 FISH, (+) indicates a positive FISH result, (-) indicates a negative result and (f) indicates that the
FISH failed because no CTCs were detected.
doi:10.1371/journal.pone.0012517.g005
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mesenchymal markers such as vimentin, EGFR and MET. With
regard to capturing CTCs from patient samples, CellSearchH and
the OncoCEE microchannel platform performed similarly (69%
and 50% prevalence of patients with CTCs, respectively), and in
both cases the captured CTCs were amenable to downstream
biomarker analysis by FISH assay. Thus, our overall results
suggested relatively similar performance in terms of CTC capture
between CellSearchH and the CTC-chip platforms in terms of
both sensitivity and yield. There are several possible explanations
as to why our findings differ from previous reports. First, some of
our comparative studies were conducted using spiked-in cell lines,
which could perform differently than CTCs from cancer patients
on these platforms, since cell lines could conceivably be more
robust than epithelial cells in peripheral circulation. Second, the
CTC-chip platforms we evaluated may have diverged from the
original platform in terms of materials used to construct the chips
as well as the layout and architecture of the microposts and the
rate of flow across the chip, possibly resulting in less efficient
capture. Third, samples in the initial CTC-chip reports were
collected and run at the same site and with no shipping step
[26,27], so it is possible that handling or delays in processing
inherent to shipping may have compromised recovery of CTCs in
our shipped samples compared to those studies. Further study will
be required to understand the key variables that impact CTC
recovery on the various platforms and determine whether
performance is comparable under a variety of conditions, but a
conclusion from our studies is that current commercially available
biochip platforms are comparable to CellSearchH for capture and
molecular characterization of CTCs.
Another challenge that must be met if CTCs are to truly have
utility for biomarker applications is that captured cells must be
amenable to commonly used biomarker assay formats such as IF,
FISH, mutation detection, and qRT-PCR. In this report, we
systematically evaluated the technical feasibility of using isolated
CTCs for these common assay formats, with particular emphasis
on the suitability of cells captured on the CellSearchH platform for
these applications, since this is an FDA approved platform and
now widely available in diagnostic labs. We found that captured
CTCs were amenable to quantitative IF scoring for both EGFR
and HER2 on the standard CellSearchH platform, and that the
levels of spiked tumor cells isolated from blood were generally
reflective of expression levels in the parent cell line. Furthermore,
we found that even in a tumor type such as NSCLC, which has
previously been reported to have a prevalence of only 20% of
patients having any CTCs [18], we were able to capture at least
one CTC and quantitate EGFR expression in blood samples from
24 out of 34 patients we evaluated. The higher prevalence of
CTCs we observed may reflect the patient population enrolled in
this clinical trial, since a recent paper reported that CTC counts in
NSCLC patients increased with tumor progression and distant
metastasis [48]. Although, evaluation of EGFR expression in
CTCs has been described previously, the data in our report is
notably different. Whereas Payne et al, looked simply at the
presence or absence of EGFR expression, we developed a
quantitative scoring criteria with four expression levels 0,1, 2
and 3 based on lung cancer cell lines that span the spectrum of
EGFR expression observed in lung cancer from an IHC score of 0
to 3. Secondly, whereas Payne et al. looked at EGFR expression in
breast cancer, we demonstrated the feasibility of this assay in lung
cancer, where CTC characterization is thought to be significantly
more difficult due to lower CTC counts. In addition, lung cancer
poses a significant need for biomarker analysis from blood due to
limited tissue availability. Taken together, our findings suggest that
quantitative assessments of protein expression for drug targets such
as EGFR and HER2 may be feasible in CTCs.
In addition, we found that nucleic acids prepared from CTCs
captured using the CellSearchH RUO Profile kit were also
amenable to biomarker assays including a qRT-PCR gene
expression assay for breast cancer molecular subtype, and a PCR-
based assay for KRAS mutations. These results suggest that in
addition to its currently approved role for prognostic testing based
on CTC enumeration, the CellSearchH platform may have utility in
capturing CTCs that can be used for predictive biomarker analyses.
An important qualification to using CTCs for molecular
biomarker detection and patient selection is that CTCs accurately
represent the molecular characteristics of the tumor mass. HER2,
in this regard, is a gold standard for biomarker validation because it
is a well-characterized marker where the metrics for HER2
positivity have been tested and correlated with response to
trastuzumab treatment [5], and FDA approved in vitro diagnostic
kits exist for HER2 testing along with ASCO/CAP testing
guidelines for appropriate testing [41]. We evaluated HER2 status
by IF in CTCs from 29 patients with advanced metastatic breast
cancer and known HER2 primary tumor status. A novel aspect of
our study is that we focused on the feasibility of HER2 testing in
CTCs from a heavily pretreated metastatic breast cancer patient
population and comparison tested the two leading CTC platforms,
CellSearchH and CTC-Chip. Although our patient population was
heavily pretreated with chemotherapy, radiation therapy and
trastuzumab, we nevertheless found 89% concordance between
HER2 status in CTCs and HER2 status from archival tumor
samples. Though the data showed generally good agreement
between HER2 status in CTCs and archival tissue, the specific
differences we observed may be due to several biological and/or
technical factors and deserve some discussion. First, marked
intratumoral heterogeneity for HER2 amplification has been well
documented and is thought to represent subclonal diversity within
tumor samples [49], so analysis of 1–5 CTCs might not be sufficient
to detect HER2+ CTCs in a heterogeneous sample. To this point,
we find that limiting analysis to samples with.3 CTCs significantly
reduces the discordance with tumor HER2 status to just one patient
using the HER2 IF assay for CTC characterization. Second,
clinical testing for HER2 is known to result in both false positives
and false negatives [41], so it is possible that some patients were
misclassified based on the original IHC test. A false negative tumor
IHC result could explain the situation in patient 6, in which all six
CTCs uniformly stained 3+ but the tumor IHC result was HER2
negative. Similarly, patients 24 and 25 were both HER2+ by IHC
but negative by CTC IF. Third, it is possible that HER2 status can
change over the course of disease progression, such that HER2
amplification is acquired later, leading to a positive test result in
CTCs in spite of a negative tumor IHC result. This could also
explain the result in patient 6. Studies that have looked at HER2
status in matched primary and metastatic tumor samples have
generally found concordance in the range of 90%, suggesting that
HER2 status is generally stable [50,51,52,53,54], but some recent
reports have shown lower concordance in the range of 60–70%,
particularly when comparing between primary tumor and CTC
HER2 status [25,30,55]. In comparison, our study reported a
slightly higher concordance at 89% between primary tumor and
CTCs. This difference may be attributable to the small sample sizes
in all of these studies (under 75 patients), or the fact that HER2
status determined by immunofluorescence is not a standardized
assay with common scoring criteria. For example, whereas we used
an H-score cutoff of 200 for HER2 positivity, another report
defined their cutoff as 50% of cells having HER2 positive
staining[30]. An implication of all of these studies taken together
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diseaseprogression insomeinstances.Notably,several patientswith
HER2 negative primary disease but HER2 positive CTCs have
been reported to show clinical benefit from trastuzumab treatment
[25], possibly suggesting some diagnostic utility of HER2
characterization in CTCs for determining eligibility for HER2-
targeting agents in patients with HER2 negative primary disease.
Overall, the data we provide in this study indicate that
molecular characterization of CTCs may have utility in biomarker
assessments in clinical trials, and that currently available platforms
have utility in the isolation of CTCs that can be used for
biomarker analyses. However, based on our assessment that .3
CTCs may be the minimum number of CTCs required to sample
heterogeneity and minimize assay error, this criteria would only be
met in about 50% of patients in both our lung and breast cancer
studies and this is an important limitation of current technologies.
In addition, based on our findings that EpCAM may be weakly
expressed in certain subtypes of cancer, current technologies that
limit capture to using EpCAM alone could significantly benefit
from adding markers of mesenchymal phenotype to improve CTC
counts and prevalence in patients. We anticipate that such
improvements in CTC technologies along with future prospective
predictive biomarker studies in CTCs from larger patient
populations with temporally matched tumor tissue and treatment
response data will conclusively establish a role for CTCs in
molecular biomarker-based patient selection.
Supporting Information
Figure S1 EpCAM expression is often lower in ovarian and lung
tumor samples with high Vimentin expression. Affymetrix gene
expression data for EpCAM from ovarian and lung tumors was
binned by low or high Vimentin expression based on cutoff at 30th
percentile. EpCAM expression was significantly lower in the
vimentin high group using Student’s t-Test in ovarian tumors
(p=0.0036) and lung tumors (p=0.012).
Found at: doi:10.1371/journal.pone.0012517.s001 (0.11 MB
DOC)
Figure S2 EpCAM expression on the cell surface is correlated
with mRNA expression a. EpCAM expression on the cell surface
by FACS analysis. b. EpCAM expression on the cell surface in
comparison to EpCAM mRNA expression in the same cell lines.
Found at: doi:10.1371/journal.pone.0012517.s002 (0.05 MB
DOC)
Figure S3 Schematic of spike-in protocol and spike-in statistics.
Found at: doi:10.1371/journal.pone.0012517.s003 (0.26 MB
DOC)
Figure S4 Correlating EGFR in CTCs with expression in parent
cell line a. H-Score for EGFR expression in CTCs correlates well
with EGFR mRNA expression in cell lines. b. H-Score for EGFR
expression in CTCs correlates well with EGFR surface expression
by FACS analysis in cell lines.
Found at: doi:10.1371/journal.pone.0012517.s004 (0.09 MB
DOC)
Figure S5 qRT-PCR assay for molecular subtyping of breast
cancer from 10 CTCs. Tumor cells from a luminal (T47D),
HER2+ (SKBR3)and a basal-like breast cancer cell line (HCC70)
or negative control (WBC) were spiked into 10 ml donor blood
and isolated using the CellSearchH platform. Cell lysates were
subjected to multi-plex qRT-PCR analysis with a panel of genes
specific for the three corresponding breast cancer subtypes.
Heatmap shows hierarchically clustered z-score normalized Ct
values for each gene.
Found at: doi:10.1371/journal.pone.0012517.s005 (0.06 MB
DOC)
Figure S6 Type I and Type II error calculated for HER2 IF
CTC assay with increasing number of CTCs, using HER2 status
in patient tumor as ‘‘truth’’.
Found at: doi:10.1371/journal.pone.0012517.s006 (0.03 MB
DOC)
Figure S7 HER2 expression is largely unchanged in replicate
sampling and on treatment with Herceptin. a. Quantitation of
HER2 immunoflourescence (IF) by H-score in replicate samples
from the same patients collected 1–2 months apart. b. HER2 IF
H-score in HER2 positive patients who were either on Herceptin
or alternate treatment (Other) at time of blood collection.
Found at: doi:10.1371/journal.pone.0012517.s007 (0.05 MB
DOC)
Table S1 Breast cancer patient and CTC characteristics. This
table contains data for all 29 patients with evaluable CTCs.
Hormone receptor status and HER2 test results is from patients
pathology reports, unless unavailable in which case HER2 status
was from information available from patient profile. Treatment at
collection date was as available from patient profiles. CTC
characteristics are as listed in Figure 6.
Found at: doi:10.1371/journal.pone.0012517.s008 (0.81 MB
DOC)
Table S2 Calculations for Type I and Type II error in the
HER2 calls in the HER2 IF CTC assay with respect to HER2
status from patient tumor. (n= number of patients, TP=
true positive, FP=false positive, TN=true negative, FN=false
negative).
Found at: doi:10.1371/journal.pone.0012517.s009 (0.05 MB
DOC)
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